14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for LCTX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.15 8.18 %
R2 1.12 5.65 %
R1 1.10 4.09 %
Current price: 1.06
Support S1 1.05 -0.95 %
S2 1.03 -2.51 %
S3 1.01 -5.03 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.30 22.64 %
R2 1.29 21.70 %
R1 1.08 1.89 %
Current price 1.06
Support S1 1.05 -0.94%
S2 1.04 -1.89%
S3 1.03 -2.83%

LCTX Predictions History

2 years ago
Labelleoutdoors predicted that LCTX for 2022-01-04 is going

Rank:

2 years ago
JS predicted that LCTX for 2022-01-03 is going $2.41 (-2.82%)

2 years ago
mpvconsult predicted that LCTX for 2022-01-03 is going

Rank:

2 years ago
Labelleoutdoors predicted that LCTX for 2022-01-03 is going

Rank:

3 years ago
JS predicted that LCTX for 2021-02-01 is going $2.24 (-4.27%)

3 years ago
anthony Gomez predicted that LCTX for 2021-02-01 is going

Rank:

3 years ago
JS predicted that LCTX for 2021-01-22 is going $2.65 (-0.38%)

3 years ago
tony karreci predicted that LCTX for 2021-01-22 is going

Rank:

3 years ago
Suman.Rauf.90671 predicted that LCTX for 2021-01-20 is going

Rank:

3 years ago
JS predicted that LCTX for 2020-12-16 is going $1.78 (-2.20%)

Click to get the best stock tips daily for free!

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa mul... LCTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT